Camille M.
- Country
- France
- Department
- Medical Oncology
Research Overview
- Phase 1/2 Study of EIK1005 Monotherapy and EIK1005 Plus Pembrolizumab in Patients With Advanced Solid Tumors
- Efficacy of Tislelizumab Versus Placebo in Patients with Molecular Residual Disease Post-Curative Therapy: A Randomized Controlled Trial
- Evaluation of EIK1004 Bis-Tartrate Monotherapy in Advanced Solid Tumors: A Phase 1/2 Dose-Escalation and Dose-Optimization Study
Data & Insights
Has run more than one trial at 19 of 75 partner sites.
Specializations
Breast cancer and HER2-directed therapy
Camille Mazza’s clinical research activity includes a broad focus on breast neoplasms, with particular interest in HER2-positive, HER2-negative, HER2-low, and triple-negative breast cancer. The work also extends to early breast cancer, metastatic breast cancer, and disease with brain or leptomeningeal metastases.
- Endocrine therapy resistance
- Circulating tumor DNA
- Antibody-based targeted therapy
- Immunotherapy combinations
Clinical interests also include CDK4/6 inhibitor-based strategies, PARP inhibitor approaches, and treatment optimization for patients with residual disease or elevated relapse risk.
Gastrointestinal oncology
The investigator is involved in studies across colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, esophageal carcinoma, small bowel adenocarcinoma, pancreatic adenocarcinoma, and biliary tract cancer. Research activity also covers anal squamous cell carcinoma and selected advanced gastroenteropancreatic neuroendocrine carcinoma.
- Metastatic colorectal cancer
- Upper gastrointestinal adenocarcinoma
- Pancreatic cancer
- Biliary tract malignancies
Therapeutic interests include chemotherapy combinations, immunotherapy, biomarker-driven treatment, and postoperative or perioperative treatment strategies in digestive cancers.
Genitourinary cancers
Camille Mazza’s portfolio includes extensive involvement in prostate cancer, renal cell carcinoma, and urothelial carcinoma. The research landscape spans castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, biochemically recurrent prostate cancer, and advanced kidney malignancies with clear-cell and non-clear-cell histology.
- Androgen receptor pathway targeting
- Immune checkpoint inhibition
- Renal cell carcinoma treatment
- Urothelial carcinoma
Additional interests include molecularly selected therapy, resistance patterns in advanced disease, and treatment strategies for patients with metastatic burden or functional vulnerability.
Gynecologic oncology
The investigator is active in ovarian cancer, endometrial cancer, cervical cancer, and related gynecologic malignancies, including recurrent, metastatic, and locally advanced presentations. Research also covers uterine leiomyosarcoma and low-grade endometrial stromal sarcoma.
- Platinum-resistant ovarian cancer
- Mismatch repair deficiency
- Hormone receptor-linked approaches
- Maintenance therapy
Therapeutic focus includes PARP inhibitor-based strategies, immune therapy, and treatment tailoring for poor-prognosis or biomarker-defined disease.
Sarcoma, thoracic cancers, and other solid tumors
Camille Mazza also contributes to research in soft tissue sarcoma, osteosarcoma, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and selected rare solid tumors. The disease spectrum includes both localized and metastatic settings.
- Radiotherapy-combined treatment
- Checkpoint inhibitor therapy
- Rare solid tumors
- Perioperative treatment strategies
Research interests further include molecular residual disease assessment, treatment adaptation in frail patients, and innovative approaches for difficult-to-treat thoracic and musculoskeletal malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.